Inceptor Bio Raises $37 Million in Series A

Inceptor Bio, a Morrisville, NC-based biotechnology company focused on cell therapies, raised $37M in Series A funding.

The round was led by Kineticos Ventures.

The company intends to use the funds to advance its CAR-T lead program to a Phase I clinical trial and continue development of its CAR-M and CAR-NK platforms. Additionally, proceeds will support completion of Inceptor Bio’s Advanced Manufacturing Platform (AMP+) facility, a 29,000 square foot, cell and gene therapy GMP manufacturing site located in Gainesville, Florida.

Led by CEO Shailesh Maingi and President and Chief Operating Officer Mike Nicholson, Ph.D., Inceptor Bio is a biotechnology company developing multiple next-generation cell and gene therapy platforms to deliver cures for underserved and difficult-to-treat cancers. By partnering with universities, medical centers, and industry leaders, Inceptor Bio advances cell and gene therapy programs from discovery-phase technologies into Phase I and II clinical assets.

Its CAR-T, CAR-M, and CAR-NK platforms are at the center of a diversified portfolio of cell therapies focused on novel mechanisms that enhance cell performance in the tumor microenvironment. Novel technologies include a co-stimulatory domain M83, proprietary TMax manufacturing process, the K62 platform, which increases the phagocytic capabilities of macrophages and supports a M1 anti-tumor phenotype, and a differentiated iPSC technology.